Skip to main content
All lobbying filings

Tiber Creek Group

Tiber Creek Group filed a Q2 report for Alnylam Pharmaceuticals, Inc. on July 19, 2026, reporting $60,000 in lobbying income.

Lobbying for Alnylam Pharmaceuticals, Inc. · Biopharmaceuticals.

As filed: TIBER CREEK GROUP for ALNYLAM PHARMACEUTICALS, INC.

All filings by Tiber Creek Group · Everything Alnylam Pharmaceuticals, Inc. has reported

 Filing · LD-2 quarterly report Q2 report
Reporting period
2nd Quarter 2026
Apr 1 - June 30 · Posted Jul 19, 2026
Income
$60,000
What the client paid this registrant for the period.
Client based in
Massachusetts

Official filing document

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 1
Medicare/Medicaid

Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing.

 Bills named in this filing 3

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem